基于异常 DNA 甲基化的常见泌尿系统癌症的诊断和预后生物标志物。
Diagnostic and prognostic biomarkers of common urological cancers based on aberrant DNA methylation.
机构信息
Department of Urology, Peking University First Hospital, Beijing, PR China.
Key Laboratory of Genomics & Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, PR China.
出版信息
Epigenomics. 2018 Sep;10(9):1189-1199. doi: 10.2217/epi-2018-0017. Epub 2018 Sep 5.
AIM
We intended to construct DNA methylation-based models for the diagnosis and prognosis of three common urological cancers including prostate adenocarcinoma, renal clear cell carcinoma and bladder urothelial carcinoma.
MATERIALS & METHODS: Total 450K methylation array data from the cancer genome atlas and gene expression omnibus datasets were downloaded. Moderated t-statistics and least absolute shrinkage and selection operator method were used to build diagnosis and prognosis models.
RESULTS
Our diagnostic panels including 128 CpG sites had high sensitivity and accuracy in distinguishing samples and could identify lymphatic metastases in prostate adenocarcinoma patients. The prognostic models with 19 CpG sites for renal clear cell carcinoma and 21 CpG sites for bladder urothelial carcinoma were able to distinguish high- and low-risk patients and improve the predictive ability of the tumor node metastasis staging system.
CONCLUSION
DNA methylation may afford reliable biomarkers in the diagnosis and prognosis of common urological cancers.
目的
我们旨在构建基于 DNA 甲基化的模型，用于诊断和预测三种常见的泌尿系统癌症，包括前列腺腺癌、肾透明细胞癌和膀胱尿路上皮癌。
材料与方法
从癌症基因组图谱和基因表达综合数据库下载了 450K 甲基化阵列数据。使用经过修正的 t 检验和最小绝对收缩和选择算子方法构建诊断和预后模型。
结果
我们的诊断面板包括 128 个 CpG 位点，具有较高的区分样本的敏感性和准确性，并能够识别前列腺腺癌患者的淋巴转移。对于肾透明细胞癌的预后模型有 19 个 CpG 位点，对于膀胱尿路上皮癌的预后模型有 21 个 CpG 位点，能够区分高风险和低风险患者，并提高肿瘤淋巴结转移分期系统的预测能力。
结论
DNA 甲基化可能为常见泌尿系统癌症的诊断和预后提供可靠的生物标志物。
Zotero 插件